|
Vaccine Detail
Bacillus anthracis mntA deletion mutant vaccine |
Vaccine Information |
- Vaccine Name: Bacillus anthracis mntA deletion mutant vaccine
- Target Pathogen: Bacillus anthracis
- Target Disease: Anthrax
- Vaccine Ontology ID: VO_0002775
- Type: Live, attenuated vaccine
- Status: Licensed
- mntA
gene engineering:
- Type: Gene mutation
- Description:
- Detailed Gene Information: Click Here.
- Preparation: An mntA deletion, generated by allelic replacement resulted in complete loss of MntA expression (Gat et al., 2005).
- Immunization Route: Other
|
Host Response |
Guinea pig Response
- Persistence: The mntA mutant resulted in severe attenuation; a 10(4)-fold drop in LD(50) in a guinea pig model (Gat et al., 2005).
- Efficacy: All the guinea pigs were challenged with 60 LD50 of the virulent Vollum strain. All guinea pigs survived this challenge and exhibited antibody titers 103−105 of either anti-PA or anti-LF (Gat et al., 2005).
|
References |
Gat et al., 2005: Gat O, Mendelson I, Chitlaru T, Ariel N, Altboum Z, Levy H, Weiss S, Grosfeld H, Cohen S, Shafferman A. The solute-binding component of a putative Mn(II) ABC transporter (MntA) is a novel Bacillus anthracis virulence determinant. Molecular microbiology. 2005; 58(2); 533-551. [PubMed: 16194238].
|
|